.jpg)
1 hour ago
2
Article content
Updated book highlights significant changes medical device developers need to know
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
PHOENIXVILLE, Pa. — Facet Life Sciences, a regulatory affairs and product development strategy partner, is proud to announce the release of the second edition of FDA and Intellectual Property Strategies for Medical Device Technologies, an updated resource for medical device innovators featuring six Facet Life Sciences experts as contributing authors.
Article content
Article content
“The journey from medical device concept to commercialization has been significantly impacted by recent key shifts in the technological landscape, including artificial intelligence (AI), the current FDA and political climate, and the ever-evolving intellectual property and US commercial environment,” says Lisa Jenkins VanLuvanee, Ph.D., Facet Life Sciences Chief Operating Officer & VP of Research and Development. “We are proud to partner with the Volpe and Koenig intellectual property team again to provide clear, comprehensive, and updated guidance to help developers progress their medical devices efficiently through development, FDA review, and into the US market.”
Article content
Article content
The second edition of FDA and Intellectual Property Strategies for Medical Device Technologies:
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
- Updates the regulations and guidances that bear on FDA medical device approval, grant, clearance, and commercialization
- Provides detailed examples of major FDA hurdles commonly encountered by medical device innovators
- Further discusses the interplay between FDA regulatory review of medical device technology and intellectual property strategy
Article content
Facet authors include Michelle Byrne, William Hodnick, Joshua Eldridge, Randy Goodman, Lisa Jenkins VanLuvanee, and Dana Blue. FDA and Intellectual Property Strategies for Medical Device Technologies: Second Edition is available online from Springer International Publishing.
Article content
About Facet Life Sciences
Article content
Article content
specializes in regulatory affairs and product development strategy for programs that challenge precedent. We help emerging biotech and life sciences teams understand what their therapies and devices must demonstrate, how FDA is likely to evaluate the evidence, and what constitutes a viable and, ultimately, approvable path forward. We bring integrated scientific, regulatory, and commercialization disciplines to guide you to and through early planning, review, and market readiness.
Article content
Article content
Article content
Article content
View source version on businesswire.com:
Article content
Article content
Article content
Contacts
Article content
Media Contact:
Lisa Jenkins VanLuvanee, Ph.D.
Chief Operating Officer & VP of Research and Development
[email protected]
Article content
English (US)